>
Floating Energy Assets Explained
What if Iran's next move against Washington is not a missile launch, but a convoy of oil tankers
Artificial Intelligence Could Transform Bank Runs From Hours-Long Crises...
Dubai Just Finished the World's First Permanent Air Taxi Route: Airport to the Marina in Under 1
Doroni Aerospace Raises More than $60m for H1?X Development
After 13 Years Battling Cancer, a 61-Year-Old Brazilian Man Achieved Complete Remission...
Extraterrestrial habitats may rise via Legos of laser-fused moon dust
Battery-only 19-seater puts China in the electric airliner race
Dream Chaser space plane gets landing approval for debut mission in 2027
SpaceX Just Caught Starship on Its FIRST Attempt!
Solid-State Cells Can Make The U.S. Competitive In Batteries Again: CEO
Jetson ONE personal eVTOL pod is about to go full sky patrol
America's INSANE BREAKTHROUGH Could Replace Septic Tanks Forever

The exciting achievement came about after researchers were able to interfere with an enzyme typically found to be overactive in the brains of Alzheimer's patients.
The hyperactive enzyme, CDK5, was treated with an unnamed peptide, or string of amino acids.
Early tests conducted on mice revealed significant — and promising — results.
"This peptide has the ability to enter the brain and in a couple of different models, the peptide shows protective effects against loss of neurons and also appears to be able to rescue some of the behavior deficits," study author Li-Huei Tsai, director of MIT's Picower Institute for Learning and Memory, told The Post.
The hope, with further testing, is that this particular peptide might be a treatment for dementia — particularly dementia brought on by CDK5 overactivity.
The errant enzyme is triggered by a smaller protein called P35, which, in Alzheimer's patients, can become harmful when "cleaved" into a smaller protein known as P25 — which is also connected to Parkinson's disease.